SecBot SecBot
425 ·Filed Jun 24, 2026

PASG

Passage BIO, Inc.
BEARISH
Impact 7/10
Horizonweeks Processed4mo ago SEC0001104659-26-077312
Rule 425 M&A communications
Actionable Insight ▼ Bearish

This is a de facto reverse merger where Passage Bio's public listing is acquired by Remix Therapeutics. Pre-merger PASG shareholders face massive dilution (~93% ownership loss) but receive CVRs tied to legacy assets. The combined entity's value depends entirely on REM-422 clinical data. Monitor the S-4 effectiveness, stockholder vote, and any competing bids for Remix given the $17.5M termination fee.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$4.33
T+0 close · Jun 24, 2026 · via day close
Latest settled
+9.70%
T+60 · $4.75
Vs SPY
+5.97%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 25 $4.33entry
  2. T+1 · 5mo ago +8.54%α +9.27% · $4.70
  3. T+5 · 5mo ago +5.77%α +4.21% · $4.58
  4. T+20 · 4mo ago +13.16%α +12.64% · $4.90
  5. T+60 · 8w ago +9.70%α +5.97% · $4.75
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Passage Bio filed a definitive all-stock merger agreement to acquire Remix Therapeutics, where pre-merger Passage shareholders will own approximately 7% of the combined company. The deal is supported by an oversubscribed $100M+ PIPE led by Decheng Capital, funding the combined entity into 2028 to advance Remix's lead oral MYB mRNA degrader REM-422. Passage shareholders receive contingent value rights tied to legacy gene therapy milestones.

Key Financial Metrics

Deal Type
merger

Key Facts

  • Passage Bio to merge with Remix Therapeutics via all-stock transaction; pre-merger Passage shareholders will own ~7% of combined company, Remix shareholders ~93%
  • Remix equity value set at $226M, Passage equity value at $20M in the merger agreement
  • Concurrent PIPE financing of at least $99,929,000 (Concurrent Investment Amount) led by Decheng Capital, with $69,999,999.28 from Subscription Agreement alone
  • Combined company will be renamed Remix Therapeutics, Inc. and focus on advancing REM-422, an oral MYB mRNA degrader showing 43% ORR in adenoid cystic carcinoma
  • Passage shareholders receive one CVR per share for potential payments from Gemma sublicenses (GM1 through July 2028, MLD through Dec 2027)
  • Passage to wind down legacy gene therapy programs (PBFT02) and dispose of Legacy Assets prior to closing
  • Passage Board recommends approval; Remix stockholders to provide written consent; Passage stockholder meeting required
  • Outside date for closing is December 24, 2026, extendable by 90 days if SEC delays S-4 effectiveness

Financial Impact

Pre-merger Passage shareholders diluted to ~7% ownership; Remix valued at $226M vs Passage at $20M; $100M+ PIPE at ~$70M from Subscription Agreement; termination fee of $17.5M payable by Remix to Passage if Remix terminates for superior offer

dilutionownershipcash runwayenterprise value

Risk Factors

  • Massive dilution for pre-merger Passage shareholders (~93% ownership loss)
  • CVRs tied to Gemma sublicenses may pay zero if milestones not met
  • REM-422 is still in clinical development with no approved products
  • Passage stockholder vote required; risk of shareholder opposition
  • Regulatory and antitrust approvals needed for merger

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
64% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
425 Filing (Primary)0001104659-26-077312
Document: tm2618476d2_ex10-6.htm0001104659-26-077312
Document: tm2618476d2_ex10-4.htm0001104659-26-077312

Track record

15 reports on PASG

Performance horizon

2 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +22.24% at T+60 after the May 27, 2026 report. 4 of 6 went positive at some point.

Filters
  1. Nov 6, 202610d ago 8-K Neutral 5/10 Entry $3.98 Now $4.13 +3.90% settles Dec 7
  2. Oct 13, 20265w ago EFFECT Neutral 3/10 Entry $3.64 to $3.78 Now $4.13 +13.46% ▲ +3.85% +7.46% vs SPY
  3. Oct 8, 20265w ago S-4/A Bearish 6/10 Entry $3.69 to $3.98 Now $4.13 −11.92% ▼ −7.72% −13.28% vs SPY
  4. Oct 5, 20266w ago S-4/A Neutral 5/10 Entry $4.08 to $3.41 Now $4.13 +1.23% ▼ −16.47% −13.56% vs SPY
  5. Sep 21, 20268w ago S-4/A Neutral 5/10 Entry $4.95 to $3.60 Now $4.13 −16.57% ▼ −27.27% −26.71% vs SPY
  6. Sep 2, 202610w ago S-4/A / 425 Bearish 8/10 Entry $4.75 to $4.12 Now $4.13 +13.05% ▲ +13.26% +12.08% vs SPY
  7. Sep 2, 202610w ago 8-K Bullish 8/10 Entry $4.75 to $4.12 Now $4.13 −13.05% ▼ −13.26% −12.08% vs SPY
  8. Jun 24, 202620w ago 425 Bearish 7/10 Entry $4.33 to $4.90 Now $4.13 +4.62% ▼ −13.16% −12.64% vs SPY
  9. Jun 24, 202620w ago 425 Bearish 7/10 Viewing Entry $4.33 to $4.90 Now $4.13 +4.62% ▼ −13.16% −12.64% vs SPY
  10. Jun 24, 202620w ago 8-K Bearish 7/10 Entry $4.33 to $4.90 Now $4.13 +4.62% ▼ −13.16% −12.64% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens in 6h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 24, 2026